Publications
Below you can find a list of our published research.
Below you can find a list of our published research.
511 results
Cited 21 times since 1989 (0.6 per year) source: EuropePMC
British journal of cancer, Volume 59, Issue 2, 1 1 1989, Pages 254-256 High dose etoposide for brain metastases of small cell lung cancer. A phase II study. The EORTC Lung Cancer Cooperative Group. Postmus PE, Haaxma-Reiche H, Sleijfer DT, Kirkpatrick A, McVie JG, Kleisbauer JP
Symptomatic brain metastases are found in about 40% of patients with small cell lung cancer. Cranial irradiation is the first line treatment for this form of metastatic disease. Frequently brain metastases recur after this treatment or develop after prophylactic cranial irradiation. For these patients no effective antitumour therapy is available. In this study the efficacy of high dose etoposide 1.5 g m-2 was evaluated. In 10 (43%) out of 23 evaluable patients a response was seen. Toxicity was s... Abstract
Cited 9 times since 1989 (0.3 per year) source: EuropePMC
Cancer chemotherapy and pharmacology, Volume 25, Issue 3, 1 1 1989, Pages 202-204 A phase II study of carboplatin and vincristine in previously treated patients with small-cell lung cancer. Smit EF, Berendsen HH, de Vries EG, Mulder NH, Postmus PE
A total of 28 previously treated patients with small-cell lung cancer were treated at relapse with 400 mg/m2 carboplatin and 2 mg vincristine on days 1 and 8, every 4 weeks. Ten partial responses (PRs) (37%) but no complete responses (CRs) were seen. Median survival after the start of second-line treatment was 120 days (range, 39-503 days). Toxicity of this regimen was moderate, including WHO grade 3/4 myelosuppression in 26% of courses (n = 66). Eight PRs were seen in a subgroup of 22 patients... Abstract
Cited 52 times since 1988 (1.5 per year) source: EuropePMC
Cancer research, Volume 48, Issue 23, 1 1 1988, Pages 6891-6899 Characterization of three small cell lung cancer cell lines established from one patient during longitudinal follow-up. Berendsen HH, de Leij L, de Vries EG, Mesander G, Mulder NH, de Jong B, Buys CH, Postmus PE, Poppema S, Sluiter HJ
Three classic-type, small cell lung cancer cell lines (GLC-14, GLC-16, and GLC-19) have been established from one patient during longitudinal follow-up. During this period the tumor changed from sensitive to completely resistant to (chemo)therapy. A phenotypical and functional characterization of the different cell lines is given in combination with the matching clinical data. (a) The cell lines have been compared with the biopsies from which they were derived. There was a good match between the... Abstract
Cited 3 times since 1988 (0.1 per year) source: EuropePMC
The European respiratory journal, Volume 1, Issue 10, 1 1 1988, Pages 969-971 An unusual cause of subcutaneous emphysema, pneumomediastinum and pneumoperitoneum. Boersma WG, Teengs JP, Postmus PE, Aalders JC, Sluiter HJ
A 62 year old female with subcutaneous emphysema, pneumomediastinum and pneumoperitoneum, was observed. Pneumothorax, however, was not present. Laparotomy revealed a large infiltrate in the left lower abdomen, which had penetrated the anterior abdominal wall. Microscopically, a recurrence of previously diagnosed vulval carcinoma was demonstrated. Despite intensive treatment the patient died two months later. Abstract
Cited 2 times since 1988 (0.1 per year) source: EuropePMC
Journal of neuro-oncology, Volume 6, Issue 3, 1 1 1988, Pages 231-232 Podophyllotoxins for brain metastases of small cell lung cancer. Haaxma-Reiche H, Berendsen HH, Postmus PE
A patient with brain metastases of small cell lung cancer (SCLC) responded initially to cranial irradiation. Recurrences were subsequently successfully treated with high-dose intravenous etoposide (VP 16-213) and teniposide (VM 26). Epipodophyllotoxins are potentially useful for CNS metastases of SCLC. Abstract
Cited 5 times since 1988 (0.1 per year) source: EuropePMC
The European respiratory journal, Volume 1, Issue 6, 1 1 1988, Pages 568-570 Benign endobronchial tumours treated by neodymium-YAG laser. Eppinga P, van der Laan KT, Overbeek JJ, Meinesz AF, Postmus PE
We present two patients with benign endobronchial tumours: polypi and a chondroma. Both were treated by Neodymium-YAG laser photoresection. There have been no signs of recurrence in the four years since treatment. Endobronchial resection by Neodymium-YAG laser is an effective treatment for benign endobronchial tumours. Abstract
Cited 3 times since 1988 (0.1 per year) source: EuropePMC
Cancer treatment reviews, Volume 15 Suppl B, 1 1 1988, Pages 41-44 Two carboplatin-containing regimens for small cell lung cancer: preliminary results of a randomized phase II trial. Postmus PE, Kirkpatrick A, Dalesio O, Palmen FJ, Carney DN, Festen J, Vendrik C, Roozendaal K, Burghouts J, Planting A
Cited 13 times since 1988 (0.4 per year) source: EuropePMC
European journal of cancer & clinical oncology, Volume 24, Issue 5, 1 1 1988, Pages 889-894 Graft versus host disease after transfusions of non-irradiated blood cells in patients having received autologous bone marrow. A report of 4 cases following ablative chemotherapy for solid tumors. Postmus PE, Mulder NH, Elema JD
In four patients with solid tumors (three small cell lung cancers, one germ cell cancer) high dose chemotherapy with autologous bone marrow infusion was given. Graft versus host disease (GVHD) was the cause of death in one patient and at autopsy signs of GVHD were found in the other three patients. In these four patients GVHD was caused by blood cell transfusion. Patients treated with aggressive chemotherapy for solid tumors are at risk for the development of GVHD after allogeneic blood cell tra... Abstract
Cited 5 times since 1988 (0.1 per year) source: EuropePMC
European journal of cancer & clinical oncology, Volume 24, Issue 5, 1 1 1988, Pages 915-921 Simultaneous standard light microscopy and immunohistology on bronchoscopically procured lung cancer specimens. Berendsen HH, De Leij L, Poppema S, Postmus PE, Sluiter HJ, The H
A method is described which enables the routine assessment of in situ phenotypic differences in lung cancer specimens. In this method, bronchoscopically procured biopsies are mildly fixated and split into two parts. One part is processed according to standard histological procedures, ensuring optimal morphology for normal pathological evaluation of the case. The other part is used for monoclonal antibody based immunohistology. The reactivity of a panel of monoclonal antibodies directed against d... Abstract
Cited 8 times since 1988 (0.2 per year) source: EuropePMC
European journal of cancer & clinical oncology, Volume 24, Issue 4, 1 1 1988, Pages 753-763 Two small cell lung cancer cell lines established from rigid bronchoscope biopsies. Postmus PE, de Ley L, van der Veen AY, Mesander G, Buys CH, Elema JD
Two new, good growing cell lines (GLC-8, GLC-11) have been established from biopsies of small cell lung cancer (SCLC). Tumor biopsies were procured by rigid bronchoscopy from tumor recurrences at the site of the primary lesions. Both tumors were clinically resistant to chemotherapy. Cytogenetic analysis revealed deletions in the short arm of chromosome 3. GLC-8 shows amplification of N-myc. Both cell lines show SCLC differentiations; neurosecretory granules were present and the SCLC related horm... Abstract
Cited 17 times since 1988 (0.5 per year) source: EuropePMC
Journal of clinical pathology, Volume 41, Issue 3, 1 1 1988, Pages 273-276 Detection of small cell lung cancer metastases in bone marrow aspirates using monoclonal antibody directed against neuroendocrine differentiation antigen. Berendsen HH, de Leij L, Postmus PE, Ter Haar JG, Poppema S, The TH
To detect metastases in the bone marrow of patients with small cell lung cancer, immunofluorescence with a monoclonal antibody detecting a membrane antigen (MOC-1) associated with small cell lung cancer was performed on 53 bone marrow aspirates from 30 patients. In 19 (63%) patients MOC-1 reactive cells were detected. Simultaneous histopathological examination of the bone marrow biopsy specimens detected tumour cells in only six (20%). The method is more sensitive than conventional histochemical... Abstract
Cited 3 times since 1988 (0.1 per year) source: EuropePMC
Chest, Volume 93, Issue 3, 1 1 1988, Pages 619-620 Intermittent atelectasis of the left lung. vd Have JJ, van der Heide JN, vd Jagt EJ, Postmus PE
Cited 254 times since 1987 (7 per year) source: EuropePMC
Nature, Volume 330, Issue 6148, 1 1 1987, Pages 578-581 Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. Kok K, Osinga J, Carritt B, Davis MB, van der Hout AH, van der Veen AY, Landsvater RM, de Leij LF, Berendsen HH, Postmus PE
In childhood malignancies such as retinoblastoma and Wilms tumour, of which both familial and sporadic forms exist, recessive mutations of presumed differentiation genes have been implicated in tumorigenesis. A proportion of cases appear with microscopically visible chromosome deletions which indicate the regions where the genes concerned are located. Mutation or loss of one allele causes a cancer predisposition. For tumour development functional loss of the remaining normal allele is also requi... Abstract
Chest, Volume 92, Issue 4, 1 1 1987, Pages 737-738 Angina pectoris and bilateral diffuse infiltrates. Lymphoplasmacytoid lymphoma. Boersma WG, van de Jagt EJ, Ilic D, Postmus PE
Cited 86 times since 1987 (2.3 per year) source: EuropePMC
European journal of cancer & clinical oncology, Volume 23, Issue 9, 1 1 1987, Pages 1409-1411 Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Postmus PE, Berendsen HH, van Zandwijk N, Splinter TA, Burghouts JT, Bakker W
In 37 patients with small cell lung cancer treatment with five cycles of cyclophosphamide, doxorubicin and etoposide (CDE), resulted in 23 complete (CR) and 14 partial responses (PR). Median response duration was 34 weeks. At relapse all patients were retreated with CDE. In 23 (62%) patients this gave a second response (6 CR, 17 PR). Factors influencing the occurrence of a second response were: 1. a CR after the first five cycles of CDE; 18 out of 23 CR patients responded again whereas only five... Abstract
Cited 16 times since 1987 (0.4 per year) source: EuropePMC
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 5, Issue 9, 1 1 1987, Pages 1445-1451 A phase I and pharmacokinetic study with 21-day continuous infusion of epirubicin. de Vries EG, Greidanus J, Mulder NH, Nieweg MB, Postmus PE, Schipper DL, Sleijfer DT, Uges DR, Willemse PH
A phase I study with continuous administration of epirubicin for 21 days using a venous access port and a portable pump was performed. The first dose step was 2 mg/m2/d for 21 days. Interval between courses was 3 weeks. Dose increment per step was 1 mg/m2/d. Twenty-two patients entered the study and received a total of 58 courses with a median of two (range, one to nine). Up to 5 mg/m2/d no toxicity (according to World Health Organization [WHO] criteria) occurred. At 6 mg/m2/d (six pts), one pat... Abstract
Cited 21 times since 1987 (0.6 per year) source: EuropePMC
Cancer genetics and cytogenetics, Volume 27, Issue 2, 1 1 1987, Pages 361-365 Loss of heterozygosity for a chromosome 3 sequence presumably at 3p21 in small cell lung cancer. Mooibroek H, Osinga J, Postmus PE, Carritt B, Buys CH
A recombinant DNA fragment detecting a chromosome #3 restriction fragment length polymorphism presumably at p21 was hybridized to HindIII-digested DNA isolated from the leukocytes of 12 patients of small cell lung cancer. Four of them appeared to be heterozygous. Analysis of tumor material from these four patients revealed homozygosity for either one or the other restriction fragment in every case. Our findings suggest the presence on the short arm of chromosome #3 of a recessive mutant cancer g... Abstract
Cited 1 times since 1987 (0 per year) source: EuropePMC
European journal of cancer & clinical oncology, Volume 23, Issue 8, 1 1 1987, Pages 1207-1208 Phase II evaluation of trans-N3P3Az2(NHMe)4 (AZP) in non-small cell lung cancer. Postmus PE, Mulder NH, Grampel JC, Meyers WH, Berendsen HH
Trans-N3P3Az2(NHMe)4 (AZP), an aziridinyl substituted cyclophosphazene, was evaluated in a phase II study in non-small cell lung cancer at a dose of .33 mg/m2 i.v. bolus every 3 weeks. There were no tumor responses seen. Cumulative bone marrow toxicity, comparable to other cyclophosphazenes, was noted. AZP is not useful for the treatment of NSCLC. Abstract
Cited 2 times since 1987 (0.1 per year) source: EuropePMC
European journal of respiratory diseases, Volume 71, Issue 2, 1 1 1987, Pages 127-129 Congenital bronchial atresia in a 66-year-old man. Aalbers R, Postmus PE, vd Jagt EJ
Cited 1 times since 1987 (0 per year) source: EuropePMC
Chest, Volume 91, Issue 6, 1 1 1987, Pages 889-890 Left paravertebral mass: giant lymph node hyperplasia. Aalbers R, vd Jagt E, Poppema S, Postmus PE